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ABSTRACT  
Chikungunya virus is an emerging arbovirus that is widespread in tropical regions and is spreading quickly to temperate 
climates with recent epidemics in Africa, Asia, Europe and the Americas. It is having an increasingly major impact on 
humans with potentially life-threatening and debilitating arthritis. Thus far, neither vaccines nor medications are 
available to treat or control the virus and therefore, the development of medicinal chemistry is a vital and immediate 
issue that needs to be addressed. The viral envelope proteins play a major role during infection through mediation of 
binding and fusion with the infected cell surfaces. The possible binding target sites of the chikungunya virus envelope 
proteins have not previously been investigated; we describe here for the first time the identification of novel sites for 
potential binding on the chikungunya glycoprotein complexes and the identification of possible antagonists for these 
sites through virtual screening using two successive docking scores; FRED docking for fast precise screening, with the 
top hits then subjected to a ranking scoring using the AUTODOCK algorithm. Both the immature and the mature forms 
of the chikungunya envelope proteins were included in the study to increase the probability of finding positive and 
reliable hits.  Some small molecules have been identified as good in silico chikungunya virus envelope proteins 
inhibitors and these could be good templates for drug design targeting this virus. 
Keywords Alphaviruses; Chikungunya virus; Envelope proteins; Virtual screening   
1. Introduction  
Chikungunya virus (CHIKV) is an emerging mosquito-borne arthrogenic member of the alphavirus genus (family 
Togaviridae) that has caused widespread outbreaks of debilitating human disease in the past five years [1]. 
Chikungunya fever (CHIKF) caused by the virus was first described in 1952 [2], and currently has been identified in 
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nearly 40 countries. In 2008 it was listed as a US National Institute of Allergy and Infectious Diseases (NIAID) 
category C priority pathogen because of the high morbidity and mortality rates and major health impact [3, 4]. 
The symptoms of chikungunya fever infection generally start 4–7 days after the mosquito bite. Infection 
usually presents in two phases; the first is acute, while the second stage is persistent (chronic), causing disabling 
polyarthritis [5]. Acute infection lasts 1–10 days and is characterized by a painful polyarthralgia, high fever, asthenia 
(weakness), headache, vomiting, rash, and myalgia [6]. The persistent chronic stage of CHIKF is characterized by 
polyarthralgia that can last from weeks to years beyond the acute stage [7]. Neurological disorders including 
encephalitis, myelopathy, peripheral neuropathy, myeloneuropathy and myopathy have also been reported [8]. 
The CHIKV genome is approximately 11.8 Kb in size and consists of a single stranded, positive sense RNA 
genome with two open reading frames (ORFs) [9], one in the 5` end which encodes two polyproteins, the precursors of 
the non-structural proteins. The second ORF at the 3` end encodes the structural proteins, the capsid (C), envelope 
glycoproteins E1 and E2 and two small cleavage products (E3, 6K). Similar to other members of the alphaviruses, the 
CHIKV starts the life cycle by entering the target host cells by pH dependent endocytosis via a receptor mediated 
interaction [10]. A recent study identified prohibitin1 (PHB1) as a microglial cell expressed CHIKV binding protein 
[11]. 
After entering the cell, the endosome acidic environment triggers conformational changes in the viral envelope 
complex made of E1 and E2 proteins, resulting in dissociation of the E2-E1 heterodimers, and the formation of E1 
homotrimers. The E1 trimer inserts into the target cell membrane via its hydrophobic fusion peptide (fusion loop) and 
refolds to form a hairpin-like structure. Exposure of the E1 fusion peptide leads to releasing of the nucleocapsid into the 
host cell cytoplasm [12],[13]. During the replication cycle inside the host cell, the capsid protein is released, and the 
pE2 and E1 glycoproteins are translated in the Golgi and are moved to the plasma membrane, where pE2 is cleaved by 
furin-like protease activity into E2 and E3 [14].  
Glycoprotein E2 is responsible for receptor binding whereas E1 is responsible for membrane fusion [4]. E3 
contains the 64-amino-terminal residues of p62 and mediates the correct folding of pE2 and its subsequent association 
with E1 [15]. E3 also protects the E2-E1 heterodimer from premature fusion with cellular membranes [16]. Furin 
maturation of p62 into E3 and E2 during transport to the cell surface primes the spikes for subsequent fusogenic 
activation for cell entry. Mature virions bud at the plasma membrane via interactions between E2 and genome-
containing viral nucleocapsids present in the cytoplasm [17], ready for infecting new cells. The crystal structures of 




Fig. 1 Crystal structure of the immature envelope glycoprotein complex of Chikungunya. Generated from the pdb file: 
3N40 [17]. 
E1 is folded into three β-sheet rich domains (I, II and III). E2 is an all β protein belonging to the 
immunoglobulin superfamily, with three domains A, B and C. Domain B is at the membrane upper end and domain C 
is towards the viral membrane: Domain A is at the centre while domain C binds to the adjacent domain II of E1. The 
long β – ribbon of E2 makes most of the connection with E3. Furin loop is E2-E3 junction in the immature complex; 
this junction contains a functional proprotein convertase motif which is cleaved by the cellular proteases; furin-like 
proprotein convertases during the maturation of the glycoproteins [14]. The amino acid His60 in this junction is the 
critical residue that determines the spectrum of furin and furin-like convertases that process E2-E3 glycoprotein 
complex [18]. The U shaped fusion loop of E1 is inserted in a groove between E2 domains A and B being stabilized by 
hydrogen bonds with E2 histidine side chains [17]. In the neutral pH, E3 maintains E2 domain B in an orientation with 
respect to domain A in such way that it creates the groove accommodating the E1 fusion loop, protecting the virus from 
premature fusion with other cellular membranes [17],[19]. Some residues in domain B of E2 are believed to be 
associated with cell recognition [16]. The fusogenic activity of the E1 fusion peptide is highly dependent on pH change. 
The histidine residues of E2 are believed to be involved as the pH sensor for the activation of the fusion protein at 
lower pH [17] due to the increased probability of histidines to become positively charged at lower pH values, based on 
the fact that the imidazole ring of the histidine residue is the only amino acid side chain whose apparent dissociation 
constant from protons (pKa) falls within the physiological range. Within the E1 fusion peptide sequence, the glycine 
residue (Gly91) is critical for the fusion process. Also, it was found that one histidine residue at E1 230, which is 
located outside of the fusion sequence, is also critical for the fusion [20].  
During the chikungunya fever, some limited symptomatic treatments including corticosteroids may be used in 
cases of debilitating chronic CHIKV infection [21],[22], and only in the last 24 months have efforts for development of 
therapeutics been reported such as arbidol [23], mycophenolic acid [24], daphnane-type diterpenoids [25], 
harringtonine [26], purines and β-lactams based inhibitors [27], and the immunostimulant polycytidylic acid [Poly 
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(I:C)]  [28]. Despite all these efforts, neither a selective antiviral drug nor a vaccine has been approved for use thus far. 
Further, no directed drug design programs have been implemented usinbg structure-based design principles and the 
newly reported CHIKV protein X-ray crystal structures. 
Blocking the in vitro CHIKV infection in the host cells targeting the envelope proteins has been demonstrated 
by blocking the intracellular furin-mediated cleavage of viral envelope glycoproteins (E2E3 or p62 precursors). This 
blocking was achieved by an irreversible furin-inhibiting peptide which significantly reduce the processing of E3E2 
CHIKV glycoproteins. This led to the formation of immature viral particles and impaired viral spreading through other 
uninfected cells [18].  This reflects the importance of considering the envelope glycoproteins as an attractive target for 
selective drug development. 
The usage of the three-dimensional structure of the target proteins (crystal structures) in the virtual screening 
(in silico) of chemical libraries has been a powerful approach to identify lead compounds with some successful 
examples in a number of systems [29, 30]. Such structure based drug design techniques, including the identification of 
new binding sites and virtual screening searches, have been successfully used for the identification of lead compounds 
for the dengue virus envelop protein (E protein) [31, 32]. Dengue virus is also an arbovirus and is transmitted by the 
same vector mosquito of the CHIKV. Herein, we report for the first time the novel binding sites in the CHIKV 
envelope glycoproteins that can be used as sites for inhibitors that could alter the function of the envelope proteins and 
consequently, inhibit the virus fusion function. To increase the chances of possible hits, we examined both the 
immature and the mature glycoprotein crystal structures for possible binding sites. Two sites were chosen that were 
common in both the immature and the mature proteins based on their locations and functions. We then used virtual 
screening combining two different docking algorithms with a number of chemical databases to identify suitable 
compounds predicted to bind in these sites. FRED (fast rigid exhaustive docking) was used for fast and precise 
screening using multiple scoring functions, followed by a re-docking ranking of the top hits using AUTODOCK 
scoring function. This led to the identification of favoured hits that have suitable binding profiles to the CHIKV 
glycoproteins. This hypothesis represents a new strategy for inhibiting this particular virus by targeting the envelope 
proteins which will lead to impaired protein function and thus inhibiting the virus, and will help the further synthetic 
development and optimization of selective inhibitors, as previously and successfully achieved for the dengue virus 
envelop protein inhibitors [32, 33].   
2. Materials and methods 
2.1. Identification of novel binding sites 
‐ 5 ‐ 
 
Both the crystal structure of the immature complex (pdb file: 3N40 [17]) and the mature complex (pdb file: 3N42 [17]) 
were used. Binding sites within the receptors were detected using the Discovery Studio 3.5 software (Accelrys Software 
Inc.: San Diego, CA, 2012). The algorithm is based on a grid search and "eraser" algorithm which derives binding sites 
from cavities in the structure of the receptor. The binding site found is displayed as a set of points. The volume of each 
cavity is defined as the product of number of site points and the cube of the grid spacing. Six main sites were detected 
in both the immature and the mature crystal structures and only one site were detected in the mature crystal structure 
that is not present in the immature form (Fig. 2). Table 1 shows the identified sites with their characters. Suitable 
cavities were then checked further based on functionality, presence of hydrophobic residues, presence of charged 
residues and solvent accessibility.  
   
Fig. 2 Crystal structure of (a) the immature glycoproteins (generated from file pdb: 3N40) and (b) the mature 
glycoproteins (generated from the file pdb: 3N42) showing the identified binding cavities as solid filled surface. 
Table 1 The identified receptor cavities in the immature (3N40) and mature (3N42) crystal structures, grid coordinates 







Site 1 (red) 
x, y, z  -15.381, -1.269, 16.434 -15.687, 2.019, -19.939 Between E1 
domain II and E2 
domain C 
Volume 687.25 651.375 
Points count 5498 5211 
Site 2 (light green) 
x, y, z -30.631, 17.481, 33.684 -33.937, -18.731, -31.939 Between E1 
domain II and the 
β–ribbon of E2 
Volume 395 357.375 
Points count 3160 2859 
Site 3 (dark green) 
x, y, z -30.631, 4.981, 37.934 -33.437, -6.731, -33.189 Adjacent to site 2  
Volume 157.625 156.125 
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Points count 1261 1249 
Site 4 (blue) 
x, y, z -38.131, 31.481, 24.934 -42.937, -28.731, -22.939 Behind the fusion 
loop, between E3, 
E2 domain B, E2 
domain A 
Volume 126.25 183.875 
Points count 1010 1471 
Site 5 (black) 
x, y, z -44.631, 14.731, 23.184 -44.437, -14.731, -23.439 between the β–
ribbon of E2 and 
E3 
Volume 93.125 124 
Points count 745 992 
Site 6 (yellow) 
x, y, z -57.631, 16.731, 36.184 -16.187, -18.231, -36.439 Within E3 cavity 
Volume 29.5 20.5 
Points count 236 164 
Site 7 (orange) 
x, y, z 
Does not exist 
-59.187, -15.731, -26.189 Replacing the furin 
loop Volume 22.25 
Points count 178 
 
2.2. Virtual screening with the CHIKV envelope proteins 
Two chemical compounds libraries were used; The NCI set library of 265,242 compounds and the Life chemicals 
protein-protein interactions inhibitors library of 31,143 compounds. The databases were filtered with the drug-likeness-
index and a limited range for the Molecular Weight < 500, calculated octanol-water partition coefficient (clogP < 5), 
and hydrogen bond donors, and acceptors (OH’s and NH’s < 5; N’s and O’s < 10) [34], using Filter v2.0.2 (OpenEye 
Scientific Software, Santa Fe, NM. http://www.eyesopen.com), producing 55,841 compounds from the NCI library 
and 4,124 compounds from the Life Chemicals library. Fast exhaustive virtual screening was performed using FRED 
v2.2.5 (OpenEye Scientific Software, Santa Fe, NM. http://www.eyesopen.com), FRED is a fast and effective 
docking application whose performance is significantly more reliable, i.e. lower variance, than most other programs 
[35, 36]. FRED performs a systematic, exhaustive, non-stochastic examination of all possible poses within the protein 
active site, filters for shape complementarily [37] and pharmacophoric features before selecting and optimizing poses 
using the Chemgauss scoring function. Omega2 (Systematic high-throughput conformer generation, OpenEye Scientific 
Software, Santa Fe, NM. http://www.eyesopen.com) [38, 39], was used to generate multiple conformers for each 
compound in the database libraries using the default settings. Omega2 takes into account the flexibility of a molecule by 
‐ 7 ‐ 
 
generating all representative conformers. For the NCI library, 2,312,012 conformers were generated, and 334,064 
conformers were generated from the Life Chemicals compounds. The work-flow diagram is shown in Fig. 3. The life 
chemical library was screened on site 2 (light green colour in Fig. 2) in both the immature and the mature 
glycoproteins. The NCI set compounds were screened on site 4 (blue colour in Fig. 2) of the two envelope protein 
forms. The binding sites were prepared for docking using Fred receptor setup software (OpenEye Scientific Software, 
Santa Fe, NM. http://www.eyesopen.com). The grid boxes were determined based on the x, y and z co-ordinates 
given in Table 1. For site 2 in the 3N40 receptor, the box size was set to 6153 Å3 and was assigned an inner contour of 
99 Å3 and an outer contour of 1886 Å3. Site 4 in the 3N40 receptor has a box size of 6580 Å3 and was assigned an inner 
contour of 116 Å3 and an outer contour of 1071 Å3. Site 2 in the 3N42 receptor has a box size of 7578 Å3 and was 
assigned an inner contour of 66 Å3 and an outer contour of 1816 Å3. Site 4 in the 3N42 receptor was assigned a box size 
of 6482 Å3, an inner contour of 45 Å3 and an outer contour of 1547 Å3. No constraints were enabled in any of the 
prepared receptors. During the docking calculations, both chemgauss3 and shapeguass scoring functions were enabled. 
After the docking calculations, the poses returned were scored and ranked with a Gaussian shape function 
independently by the five available scoring functions (PLP, Chemgauss3, Chemscore, OEChemscore, and Screenscore) 
and by a consensus of all. The top ranked poses from the exhaustive docking were then optimized using systematic 
solid body optimization by chemgauss3. VIDA v4.2.0 (OpenEye Scientific Software, Santa Fe, 
NM. http://www.eyesopen.com) was used to visualise the docked poses within the receptor active site, and to inspect 
the critical interacting residues in each pocket with the individual docked poses. Top 20 hits were then recorded for 
each of the four sites (data not shown). 
The top 20 docked poses ranked in each of the four binding sites were then extracted as pdb files, and were processed 
with AutoDock Tools 1.5.6rc3 (ADT) graphical interface [40]. The Gasteiger charges were calculated and the nonpolar 
hydrogen atoms were merged, torsion angles were defined, they were then saved as pdbqt files for Autodock 
calculations. Crystal structures (3N40, 3N42) were used by AutoDock Tools 1.5.6rc3 to setup the receptor binding 
sites. The grid box co-ordinates in each site were determined based on the co-ordinates in Table 1. The grid box size 
was set to 46 x 46 x 46 points in x, y, and a z direction in each of the four sites and a grid spacing of 0.375 Å was used. 
AutoGrid 4.2 algorithm was used to evaluate the binding energies between the inhibitors and the enzyme and to 
generate the energy maps for the docking run. Fifty runs were generated by using Autodock 4.2 Lamarckian genetic 
algorithm [40] for the searches. Cluster analysis was performed on docked results, with a root-mean-square tolerance of 
2.0 Å, the docked poses were ranked according to the binding energies and ligand efficiencies, and finally the five 
lowest energy poses (Tables 2-5) were selected as the resultant complexes with the proteins. The complexes were then 
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typed with the CHARMm forcefield with Discovery Studio 3.5 software (Accelrys Software Inc.: San Diego, CA, 
2012) to relax the obtained poses within the protein pockets, and visualized. Fred and Autodock are powerful tools for 
the preliminary identification of hits [41], and have previously been used together successfully for the in silico 
identification of potential inhibitors [42]. Compounds are commercially available and have drug like qualities and also 
can be accessed through chemical syntheses for further optimization process. 
 
Fig. 3 Work-flow diagram of the virtual screening procedures used for CHIKV envelope proteins. 
Table 2 Top 5 hits identified for site 2 using the immature glycoprotein receptor (3N40), showing the molecular 




















































*Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada). 
Table 3 Top 5 hits identified for site 2 using the mature glycoprotein receptor (3N42), showing the molecular weights, 





















































*Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada). 
#Numbers of E2 residues in the mature form are different than the corresponding residues in the immature form. 
 
Table 4 Top 5 hits identified for site 4 using the immature glycoprotein receptor (3N40), showing the molecular 






















































*Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada). 
Table 5 Top 5 hits identified for site 4 using the mature glycoprotein receptor (3N42), showing the molecular weights, 



















































*Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada). 
#Numbers of E2 residues in the mature form are different than the corresponding residues in the immature form. 
3. Results and discussion 
The essential role of the CHIKV envelope protein in the fusion process, its location on the surface of the mature virus 
(spikes) and the availability of the crystal structures make it a suitable target for structure-based drug design. The 
CHIKV glycoprotein exists in two forms, the immature form and the mature form. The immature form represents the 
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early stages of the envelope protein after the replication cycle, translated in the endoplasmic reticulum and processed in 
the Golgi for maturation, moved to the plasma membrane, where it is cleaved by furin-like protease activity in the host 
infected cell into E2 and E3 [14]. The furin cleavage occurs at the furin loop, which represents the junction between 
E2-E3. The difference between the two crystal structures is the removal of the furin susceptible peptide motif which 
results in slight changes in the volumes of the predicted binding sites. We searched for possible binding sites within 
both the immature and the mature crystal structures. Six common sites were detected in both structures (Table 1). 
Among the detected sites, site 2 (light green, Fig. 2) and site 4 (blue, Fig. 2) were interesting. Site 2 represents a surface 
cavity that lies between the E1 domain II and E2 β–ribbon that connects E2 domain A to E2 domain C; also extends 
downwards as a channel between E1 domain II and E2 domain A. E2 domains A and B move relative to each other in 
the pre- and post-fusion structures. Therefore, small molecules that bind to this site may stabilize the E1-E2 
heterodimer and prevent their dissociation during the fusion process. An additional hypothesis is that it may also 
stabilize the orientation of E2 domain A with respect to domain B in a way that inhibits the exposure of the fusion 
peptide in conditions of low pH in the endosome, preventing the fusion process. Moreover, being a groove in this area 
looking like the enzyme mouth (Fig. 4), bound small molecules in this site might act as indirect allosteric inhibitors for 
the furin susceptible peptide motif, and therefore, might impair the cleavage step by the furin proteases. The indirect 
allosteric inhibition mechanism might be through the inhibition of the interaction between the CHIKV envelop protein, 
and hence the furin susceptible motif (furin loop), and the acting protease (therefore, the Life Chemicals protein-protein 
inhibitors library was used here), or through trapping the glycoprotein conformation in one inactive form (relative to the 
furin cleavage step), which does not interact with the acting proteases. The site 2 volume in the immature form is 9.5% 
bigger than that in the mature form. Therefore, both structures were included in the virtual screening study in an attempt 




Fig. 4 Surface representation of the location of site 2 (green colour), parts of E2 and E3 are shown in orange colour 
where the furin loop takes a greyish orange colour at the top, E1 domain II surface is shown in grey colour. Site 2 is 
located in a mouth like cavity that might interact during the furin cleavage. Generated from the pdb file: 3N40 [17]. 
 Site 2 makes close contact with residues from E1 and E2. The E1 residues are: Glu50-Val60, Val229-Pro237; 
the E2 residues are: Ala97-Arg102 (corresponds to Ala33-Arg38 in the mature form), Gln300-Arg308 (Gln236-Arg244 
in the mature form). Hydrogen bonding within these residues involve E1 Lys52, Thr53, Ile55, Val231, His230, and E2 
Tyr301 (Tyr237 in the mature form), Glu232 (Glu168 in the mature form), and Arg100 (Arg36 in the mature form. 
Val54, Lys52, Arg100, Ile167 are able to form other types of strong noncovalent molecular interactions. Generally, 
valine, alanine and proline amino acids within this pocket are also able to participate in the hydrophobic interactions.   
Surprisingly, we could not find a common hit ligand that fits in site 2 in both the immature and the mature 
forms. However, inspection of the top 5 docked poses in each site reveals that they have the common sequence: 
heterocycle-S-CH2-CO-N, the amidic nitrogen in this sequence might be NH, and also can be a part of another ring 
system, Fig. 5 shows the 2D representations of the top docked poses in site 2 for both the immature and the mature 
forms of the envelope glycoproteins. The presence of an electron rich system results in strong noncovalent molecular 
interactions, e.g. the π-cation interaction between E2 Arg100 (Arg36 in the mature form) and E1 Lys52. The 
heterocyclic ring adjacent to the sulphur in most of the top ranked poses can accept H-bonding with E1 Lys52, Ile55, 
and Thr53. Being able to bind to residues in both E1 and E2, the ligands identified for this site are most likely to 
confirm our hypothesis and stabilize the E1-E2 heterodimer and prevent the dissociation. 
     
Fig. 5 2D representation of the docked poses within the binding site 2. (a) Top ranked pose (number 1 in Table 2) 
within the immature glycoprotein complex site 2. (b) Top ranked pose (number 1 in Table 3) within the mature 
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glycoprotein binding site 2. H-bonds are shown in green and blue dashes, while π interactions are shown as orange 
lines. 
Site 4 (blue, Fig. 2) can be described as a narrow channel extending just behind the fusion loop and surrounded 
by both E2 domains A and B. Comparison between the two sites in the immature and the mature forms indicates that 
the site volume is 31.3% bigger in the mature form (Fig. 2), which is sufficiently significant to indicate the changes 
occurring after maturation (cleavage of the furin loop), which looks like an umbrella above this site in the immature 
form. Small molecules binding to this narrow channel will have significant effects; this might not only freeze the 
relative movement of E2 domains A and B, but might also freeze the fusion loop through stabilizing interactions, and 
consequently, prevent the exposure of the fusion loop. The fusion loop is stabilized by the histidine residues of E2, 
which act as the pH sensors for the activation of the fusion protein at lower pH [17] where the histidine residues 
become protonated. This site cavity lies in contact with several histidine residues of E2. Therefore, blocking this site 
may also impair the pH sensor activation mechanism. All the identified hits were found to bind to both E1 and E2 
residues, involving the histidine residues of E2, moreover, two hits were found to bind to the fusion loop amino acids, 
confirming the ability of freezing the fusogenic activity of the envelope proteins. 
 Site 4 forms close contact with the E1 fusion loop residues Pro86-Gly91, E1 Gly227-His230. The fusion loop 
Gly91 and His230 (outside of the fusion sequence) were found to be critical for fusion [20]. This emphasises the 
importance of our hypothesis that binding to this site will impair the fusion process. From E2, residues Arg77-His82 
(Arg13-His18 in the mature form), Ser91-Val96 (Ser27-Val32 in the mature form) and residues Leu305-Ala310 
(Leu241-Ala246 in the mature form) form close contacts with the binding site. 
 Interestingly, a common hit ligand was found in both the blue sites (ranked 5 in table 4, and ranked 2 in table 
5). It shows the same interactions within the two binding pockets and more importantly, it forms two H-bonds (2.05, 
2.13 Å) with E1 fusion loop amino acid Phe87, 3 amino acids away from Gly91, the critical [20] residue for the fusion 
process. It also binds to E2 His82, His93 (His18, His29 in the mature form) via H-bonding and π-cation interactions 
(Fig. 6). Moreover, the predicated binding affinity and inhibitory constant (Ki, in the nanomolar range), along with the 





Fig. 6 3D representation of the predicted docking pose of compound 2 (Table 5) within site 4 binding pocket 
(transparent surface) of the mature chikungunya envelope protein showing the H-bonding (green dashes) with the 
fusion loop amino acid Phe87 (shown in orange). 
A further interesting observation is the presence of same chiral skeleton; the (S)-1-(2-hydroxy-3-
phenoxypropyl)-4-phenylpiperazin-1-ium in a series of compounds (1, 2 and 3 in Table 4) and (3, 4 in Table 5). The 
compounds only differ in the substituents on the terminal phenyl rings. The chirality of this series indicates the 
selectivity of the compounds and reflects the importance of the stereochemistry in designing inhibitors for this site. The 
enantiomers of these compounds (within the library) did not pass the first FRED virtual screening (data not shown). 
Within the immature narrow binding pocket (site 4), these series was able to form H-bonds with the E1 Val229, E2 
His82, E2 Leu305. However, in case of the 31.3% bigger pocket of the mature site 4, this series was able to achieve the 
H-bonding with E1 Val229, E2 His29 whereas it failed to form H-bonds with the E2 Leu241, but was still able to 
achieve the π-stacking interaction with E2 His18 and His29 (Fig. 7). The importance of this stereo-selectivity in 
inhibiting the envelop protein, was also noticed recently in the inhibitors of the dengue virus envelop proteins mediated 
fusion, where compounds with certain stereochemistry of the OH group (the (S) enantiomers) were shown to have 
special effects on the activities [43]. The importance of the (S) configuration of the compounds (Fig. 7) can be referred 
to the ability of the OH groups of the compounds to achieve H-bonds with the E2 histidine residues (His82 of the 
immature form and His29 of the mature form), whereas these H-bonds might not be possible with the other 
enantiomers. Superimposition of the two compounds (number 1 in Table 4 and number 3 in Table 5) within the binding 
pockets (site 4 in both enzyme forms) revealed that the positioning of the docked poses were very similar, with slight 
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changes in the orientation of the hydroxyl groups and the central piperazinium moiety (Fig. 8). This superimposition 
not only indicates the reliability of the interactions of this class of compounds with the residues within this site in the 
two forms of the enzyme, but also confirms our hypothesis that this series might be developed as selective CHIKV 
envelope protein inhibitors. 
      
Fig. 7 2D representation of the docked poses within the binding site 4. (a) Top ranked pose (number 1 in Table 4) within 
the immature glycoprotein complex site 4. (b) Top ranked pose (number 3 in Table 5) within the mature glycoprotein 
binding site 4. H-Bonds are shown in green and blue dashes, while π interactions are shown as orange lines.  
 
Fig. 8 Superimposition of compound 1 (in Table 4) within the immature glycoprotein site 4 (compound and residues are 
shown in violet colour) and compound 3 (in Table 5) within the mature glycoprotein binding site 4 (compound and pocket 
residues are shown in green colour). Slight differences can be seen for the orientation of the hydroxyl groups and the 
central piperazinium ring. 
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Although ranked 5 in Table 5, this ligand shows extraordinary H-bonding (2.41 Å) with the fusion peptide 
amino acid Trp89, just one amino acid away from Gly91, the critical [20] amino acid for the fusion process (Fig.9). The 
pose is also stabilized inside the pocket by the interactions with the E2 His18, His29 and Leu16 (Table 5). This also 
emphasises the possibility of inhibiting the fusion process through designing ligands for this pocket.  
 
Fig. 9 Pose 5 (Table 5) within the mature glycoprotein binding site 4 (transparent surface), showing the 2.41 Å H-bond 
interaction (yellow line) with Trp89. Gly91 is shown in orange. 
4. Conclusions  
Thus far, the CHIKV envelope protein has not been investigated as a possible target for the drug design against the 
virus. Therefore, we have investigated for the first time the possible binding target sites within the immature and the 
mature forms of the CHIKV envelope proteins. We managed to identify two sites that look critical to the protein 
functions; mainly the fusion process, based on the functionality and the location of the sites. We also have run a virtual 
screening on the two sites in both forms of the enzymes to increase the chances of finding reliable positive hits. Five 
hits for each site in both forms of the CHIKV envelope proteins were identified revealing some important features for 
further developing antagonists for these proteins. To test our hypothesis, the identified hits need to be evaluated against 
the CHIKV, which is currently under investigation. Our study represents a good template for designing selective 
inhibitors for the chikungunya virus envelope proteins via in silico and in vitro optimization process. Our hypothesis 
might also be a useful tool for inhibiting other alphaviruses such as Sindbis virus and Semliki Forest virus as well as 
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